February 20, 2025

A statement from the cooperative groups

February 14, 2025

From the group co-chairs of ECOG-ACRIN: A perspective on indirect costs (requires subscription)

February 6, 2025

“I was delighted when I saw the results. Positive phase 3 trials in glioma are a rarity.” David Schiff on the results of E3F05

January 17, 2025

The Winter 2025 advocacy blog Considering Clinical Trials is now available

January 15, 2025

Press Release: Large-scale TMIST breast cancer screening trial achieves enrollment goal, paving the way for data that provides a precision approach to screening

More than 108,000 women across the world joined the TMIST breast cancer screening trial of 2-D versus 3-D mammography
December 18, 2024

How ECOG-ACRIN and Caris Life Sciences are teaming up to fight cancer

December 13, 2024

Tamoxifen cuts 15-year recurrence in DCIS without radiation therapy

December 12, 2024

Press Release: Adjuvant tamoxifen may reduce recurrence risk for patients with ‘good-risk’ DCIS who forgo radiation

December 11, 2024

Does acalabrutinib fit into frontline therapy for patients with mantle cell lymphoma? (Study EA4181)

ECOG-ACRIN Cancer Research Group